Agency: European Commission | Branch: H2020 | Program: CSA | Phase: SC1-HCO-02-2016 | Award Amount: 2.08M | Year: 2017
Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, storage, transport, processing etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients samples with post collection changes in cellular and extra-cellular biomolecules profiles thus often making diagnostic test results unreliable or even impossible. To tackle this, SPIDA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/Technical Specifications and ISO/International Standards, addressing the important pre-analytical workflows applied to personalized medicine. These will also applicable to biomarker discovery, development and validation as well as to biobanks. Corresponding External Quality Assurance (EQA) Schemes will be developed and implemented as well, aiming to survey the resulting quality of samples and diagnostic practice. SPIDIA4P will ensure stakeholder organisations involvements as well as training, education, and counselling as additional major foci of the project. The consortium will closely coordinate with large European public research consortia to obtain access to research and validation studies data serving as evidence for the new standards developments and achieved improvements of diagnosis, patient stratification and prognosis of disease outcome. At this crucial moment in the development of personalised medicine, SPIDIA4P proposes a coordination and support action that reunites 19 highly experienced partners in international standardisation for in vitro diagnostics, coming from private industry including SMEs, public institutions and from one official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on personalised medicine.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.2.2-01 | Award Amount: 7.65M | Year: 2012
The main objective of the BACCHUS project is to develop tools and resources that will facilitate the generation of robust and exploitable scientific evidence that can be used to support claims of a cause and effect relationship between consumption of bioactive peptides and polyphenols, and beneficial physiological effects related to cardiovascular health in humans. To achieve this, the BACCHUS consortium has assembled 12 leading Research & Technological centres and 16 SMEs (with ca 30% of the EC requested contribution allocated to the SMEs). BACCHUS thus contains SMEs directly involved in developing food products and pursuing health claims, experts in health claims legislation and the EFSA review process, and academic and industry partners who provide high quality food and health research that can underpin health claims. Existing SME-developed products that have clear potential for obtaining favourable opinions for health claims have been selected as test cases for study. These have been aligned with a series of work-packages each of which addresses key aspects of the EFSA health claim evaluation process (legislation and dossiers; product/bioactive characterisation; habitual intakes; bioavailability; mechanisms and biomarkers; clinical trials evidence of health benefit) that will deliver tools, processes and high quality original science. Scientific results and best practice guidelines will be made publically available and thus support future claims for industry. The scope and completeness of the existing bioactive database (eBASIS) that includes both compositional and biological effects data will be extended and developed as a sustainable tool with various training materials. All outcomes will be disseminated broadly by direct engagement with SMEs via an existing European SME association, with stakeholders via seminars, newsletters and press releases, as well as through traditional scientific routes (high quality publications, and conference presentations).
Agency: European Commission | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2012-IAPP | Award Amount: 871.61K | Year: 2013
Microbial communities are microorganisms (viruses, bacteria, fungi, algae) at the base of the food web pyramid, representing about 50 % of the total biomass on Earth. They are responsible for the biogeochemical cycles that shape the environment of earth and of its aquatic systems, influencing the health of each trophic and ultimately human health, too. In Europe, the good quality of surface waters is established under the Water Frame Directiv (WFD) based either on the chemical monitoring, or on the ecological status and pathogen detection in drinking and bathing waters. However, methods and techniques currently used for monitoring water quality and to detect potential biohazards present several limitations due to the need of highly skilled technicians; the long time for obtaining results, and the lack of tools for an integrated monitoring and evaluation of all different biological and non biological parameters relevant to guide preventive/remediation actions by the water authorities. MicroCokit, a close collaboration of academic groups with pan-European governmental laboratories and leading private enterprise, has been conceived to foster the transfer of knowledge among the partners with the final goal to bring to market faster, more sensitive and robust tools as bioindicators of water quality. The tools will be developed according to three different kind of bioindicators, 1) Microbial community bioindicator; ii) Pathogen indicator; iii) Early warning bioindicators for bacteria, cyanobacteria, and diatoms. The end-products will be of two kinds: a ready to use plate containing defined primers for quantitative Real Time PCR (qPCR) targeting the developed bioindicators and probes for Fluorescence in situ hybridization technique (FISH). The participation of two private enterprises already active in the field of molecular biology diagnostics, will facilitate the translation of this innovative ideas and tools into real products that will benefit European society.
LCG Group and University of Southampton | Date: 2014-06-18
There is provided a method of detecting the presence of a target polynucleotide and/or sequence variations within the target polynucleotide using a probe system comprising two independent partner oligonucleotide components wherein the first oligonucleotide has a first and second section, wherein the first section comprises a nucleotide sequence that is labelled with at least one visually detectable label and is not capable of hybridising to the nucleotide sequence of the target polynucleotide; and wherein the second section comprises a nucleotide sequence that is capable of hybridising to a portion of the sequence of the target polynucleotide; and the second oligonucleotide has a first and second section, wherein the first section comprises a nucleotide sequence which is capable of hybridising to a nucleotide sequence of the first section of the first oligonucleotide; and the second section comprises a nucleotide sequence that is capable of hybridising to a nucleotide sequence of the target polynucleotide that is adjacent to the nucleotide sequence that the second section of the first oligonucleotide is capable of hybridising to. There are also provided alternative methods using additional oligonucleotides and probes for use in such methods.
LCG Group | Date: 2012-06-18
In many situations, particularly in forensic science, there is a need to consider one piece of evidence against one or more other pieces of evidence. For instance, it may be desirable to compare a sample collected from a crime scene with a sample collected from a person, with a view to linking the two by comparing the characteristics of their DNA, particularly by expressing the strength or likelihood of the comparison made, a so called likelihood ratio. The method provides a more accurate or robust method for establishing likelihood ratios through the definitions of the likelihood ratios used and the manner in which the probability distribution functions for use in establishing likelihood ratios are obtained The methods provide due consideration of stutter and/or dropout of alleles in DNA analysis, as well as taking into consideration one or more peak imbalance effects, such as degradation, amplification efficiency, sampling effects and the like.
LCG Group | Date: 2012-05-22
A method for comparing DNA containing test results and stored results is provided, including a) a stored result selection and plurality of stored result database creation stage; b) a test result against stored result comparison stage, including: 1) A test result selection and plurality of test result database creation sub-stage; 2) A single test result database against single stored result database search sub-stage, performed for the various pairs of test result databases and stored result databases, to establish matches; 3) An established match review sub-stage, to filter out established matches which do not feature as matches across the other test result against stored result databases; 4) A process outcome sub-stage which provides details of the matches which extend across all the database pairs.
LCG Group | Date: 2011-03-10
In many situations, particularly in forensic science, there is a need to consider one piece of evidence against one or more other pieces of evidence. For instance, it may be desirable to compare a sample collected from a crime scene with a sample collected from a person, with a view to linking the two by comparing the characteristics of their DNA, particularly by expressing the strength or likelihood of the comparison made, a so called likelihood ratio. The method provides a more accurate or robust method for establishing likelihood ratios through the definitions of the likelihood ratios used and the manner in which the probability distribution functions for use in establishing likelihood ratios are obtained. The methods provide due consideration of stutter and/or dropout of alleles in DNA analysis, as well as taking into consideration one or more peak imbalance effects, such as degradation, amplification efficiency, sampling effects and the like.
LCG Group | Date: 2011-06-17
A method for amplifying nucleic acid from a higher eukaryotic, such as mammalian or plant, nucleic acid source, the method comprising (a) contacting a sampling device with the source of higher eukaryotic, such as mammalian or plant, nucleic acid such that following said contacting, higher eukaryotic such as mammalian or plant nucleic acid-containing material is adhered to at least part of the sampling device, wherein the sampling device, or part thereof to which the nucleic acid-containing material is adhered, is made of a suitable polymeric material; (b) introducing the sampling device or part thereof to which the nucleic acid-containing material is adhered into a reaction vessel which contains a reaction mixture for carrying out a nucleic acid amplification reaction, without any prior treatment of the nucleic acid-containing material; and (c) performing a nucleic acid amplification reaction.
LCG Group | Date: 2014-08-27
There is provided a single stranded oligonucleotide having a 5 end and a 3 end, said oligonucleotide comprising a first and second section, the first section being positioned 5 of the second section; and wherein (i) the first section is labelled with at least two detectable labels and is capable of hybridising to a target polynucleotide; and (ii) the second section is not capable of hybridising to a target polynucleotide; said second section comprising a stem-loop structure comprising a first portion, a second portion and a third portion and wherein the second portion is located between the first and third portions, and the first and third portions are complementary to each other. There is also provided a method of detecting the presence of a target polynucleotide and/or sequence variations within a target polynucleotide using such an oligonucleotide.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 134.38K | Year: 2011
The CLIENT project sets out to achieve a platform for rapid in-clinic STI analysis so as to enable a test and treat service within the clinic whilst the patient briefly waits. The project, led by LGC, is assembled through 7 parallel Work Packages shared amongst the 4 partnering teams to the project. On the technical front the key challenge is to build on the rapid and sensitve sequence-specific detection achieved by HyBeacon probe technology with either isothermal or PCR methodology for simple end-user operation. This will then be partnered with approriate amplification instrumentation and sample preparation. Evaluation of amplification methods is being led by LGC with the University of Southampton School of Chemistry focussing on improvements to existing probe technology. The point-of-care instrumentation is being developed by OptiGene to partner the probe technology and the Chlamydia Research group the University of Southampton are providing expertise in STI handling and sample prep as well as insight into end-user requirments.